Ilenozyd

Linezolid, the active ingredient in Ilenozyd, is an oxazolidinone presented as an oral dosage form for systemic use. It treats serious bacterial infections caused by resistant Gram‑positive organisms, including MRSA and VRE, in adult patients.

GNH USA supplies Ilenozyd as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linezolid is indicated for infections caused by resistant Gram‑positive bacteria, acting within the antibacterial therapeutic class. - Methicillin‑resistant Staphylococcus aureus (MRSA) infections: provides bacterial eradication and clinical resolution. - Vancomycin‑resistant Enterococcus (VRE) infections: achieves effective clearance of resistant enterococcal strains. - Community‑acquired pneumonia: improves respiratory symptoms and eliminates causative pathogens. - Skin and soft‑tissue infections: reduces lesion size and promotes healing. - Complicated skin and soft‑tissue infections: resolves infection and prevents systemic spread.

Linezolid may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools, occasionally watery. - Headache: transient cranial discomfort. - Metallic taste: altered taste perception. - Vomiting: occasional emesis. - Rash: mild skin erythema.

Serious or Rare Side Effects: - Thrombocytopenia: significant reduction in platelet count. - Peripheral neuropathy: numbness or tingling in extremities. - Serotonin syndrome: risk when combined with serotonergic agents. - Optic neuritis: visual disturbances and eye pain. - Myelosuppression: bone‑marrow suppression affecting blood cells. - Lactic acidosis: metabolic acidosis with elevated lactate levels.

Before initiating therapy, clinicians should assess patient‑specific risk factors and monitor relevant parameters. - Monitor blood counts: regular CBC to detect thrombocytopenia or anemia. - Assess renal function: adjust therapy in patients with impaired clearance. - Evaluate for serotonergic drug use: avoid concurrent serotonergic agents. - Use caution in history of myelosuppression: consider alternative therapy if prior bone‑marrow toxicity. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Linezolid interacts with several drug classes; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Serotonergic agents (SSRIs, SNRIs, TCAs, tramadol): potential serotonin syndrome. - Rifampin: reduces linezolid plasma concentrations, compromising efficacy.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Phenytoin: may lower linezolid levels, necessitating efficacy assessment. - Carbamazepine: possible reduction in linezolid exposure. - NSAIDs: increased bleeding risk when combined with thrombocytopenia.